Table 2.

Cholesterol-lowering drugs associated with decreased risk for LBD in the 3-year lag model

Drug name	Exposed cases	Exposed controls	Unexposed cases	Unexposed controls	OR (95% CI)	P-value	Drug class(es)
Colesevelam HCL	447	3214	123 900	908 766	0.77 (0.70–0.83)	2.00E−14	Bile acid sequestrant
Amlodipine/atorvastatin calcium	692	6128	123 655	905 852	0.69 (0.63–0.74)	1.58E−42	Calcium channel blocker/HMG-CoA reductase inhibitor
Fenofibrate	360	2920	123 987	909 060	0.67 (0.58–0.75)	2.40E−22	Fibrate
Fenofibrate nanocrystallized	2726	18 577	121 621	893 403	0.74 (0.72–0.77)	6.46E−86	Fibrate
Fenofibrate, micronized	414	2598	123 933	909 382	0.82 (0.74–0.89)	2.19E−07	Fibrate
Fenofibric acid (choline)	156	1147	124 191	910 833	0.48 (0.35–0.62)	8.51E−26	Fibrate
Gemfibrozil	1816	13 254	122 531	898 726	0.80 (0.76–0.83)	1.17E−36	Fibrate
Atorvastatin calcium	18 562	133 503	105 785	778 477	0.89 (0.88–0.90)	6.31E−82	HMG-CoA-reductase inhibitor
Ezetimibe/simvastatin	4466	35 904	119 881	876 076	0.79 (0.76–0.81)	5.13E−107	Cholesterol absorption inhibitor/HMG-CoA-reductase inhibitor
Fluvastatin sodium	915	6408	123 432	905 572	0.91 (0.86–0.95)	3.89E−05	HMG-CoA reductase inhibitor
Pravastatin sodium	4897	35 149	119 450	876 831	0.90 (0.88–0.92)	1.02E−21	HMG-CoA reductase inhibitor
Rosuvastatin calcium	4870	37 077	119 477	874 903	0.82 (0.80–0.84)	1.78E−76	HMG-CoA reductase inhibitor
Simvastatin	21 867	143 640	102 480	768 340	0.97 (0.96–0.99)	1.17E−05	HMG-CoA reductase inhibitor
Ezetimibe	4529	34 260	119 818	877 720	0.79 (0.77–0.81)	1.74E−100	Intestinal cholesterol absorption inhibitor
Niacin	1460	10 975	122 887	901 005	0.84 (0.80–0.87)	1.58E−21	Niacin
Niacin/lovastatin	220	1688	124 127	910 292	0.75 (0.65–0.85)	7.94E−09	Niacin/HMG-CoA reductase inhibitor